Best Stocks: Three healthcare names to ponder including a biotech back to levels not seen in a decade

(This is The Best Stocks in the Market , brought to you by Josh Brown and Sean Russo of Ritholtz Wealth Management.) Josh here — The healthcare sector has entered the chat. There are 12 healthcare names now on our Best Stocks list as of the end of last week. I'll show you a few of these set-ups below and then Sean's going to share some fundamentals for these healthcare firms. Sector Leaderboard As of 6/9/2025 morning, there are 114 names on The Best Stocks in the Market list Top Sector Ranking: Top Industries: Top 5 Best Stocks by Relative Strength: Sector Spotlight: Healthcare Josh — Alnylam Pharma (ALNY) just broke out above prior resistance at $300. There was company-specific news about new indications for one of their most important drugs that led to multiple price target raises on The Street. Alnylam is named for Alnilam, the brightest star in the Belt of Orion constellation, which ancient mariners used for navigation. The founders of the company believed their trailblazing work in the field of RNA interference (RNAi) would chart a brand new course of drug discovery and development by which the next generation of scientists would be guided. So far, so good as ALNY grew revenue to $2.25 billion in revenue last year and the company's market cap swelled to a respectable $40 billion. Wall Street's median price target is ten percent higher than today's price while the most bullish analyst, H.C. Wainwright, just published a target of $500 this past week. In Q1 2025, revenue surged by over 28% year-over-year to approximately $594 million, driven largely by the strength of the TTR franchise. Looking ahead, analysts project revenue growth of 24–33% through 2025–2026, supported by improving EPS and an expected annual revenue of $2.9 billion. The company also maintains a strong balance sheet, with around $223 million in free cash flow, a quick ratio of approximately 2.7×, and increasing support from major institutional investors who are adding to their positions. (data via Reuters) Sean — AMVUTTRA (vutrisiran) was recently FDA‑approved for cardiomyopathy, expanding its market from neuropathy, which is a major catalyst for the stock — it significantly expands its addressable market beyond its original use for polyneuropathy. This approval allows Alnylam to target patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a much larger population than those with ATTR polyneuropathy. The drug's unique RNA interference mechanism and dosing schedule (quarterly or biannual injections) give it a competitive edge over existing therapies like Pfizer's Vyndaqel. This dual-indication approval not only boosts Alnylam's revenue potential but also strengthens its path toward profitability, making AMVUTTRA a key growth driver for the company and a pivotal reason for recent momentum. Josh — Allow for short-term consolidation in the $300 area, await the next catalyst. 50-day crossing over 200-day important signal that a new uptrend could be forming. Cardinal Health Josh — All three major Pharmaceutical Wholesalers made the list - McKesson (MCK) , Cencora (COR) and Cardinal Health (CAH) , only Cardinal looks good technically right now: CAH held its 50-day on a weekly closing basis during the April bloodbath, I'd use that area as a stop and update it each week. If the uptrend breaks, there's no reason to be long. Sean — CAH is a $37 billion wholesaler, sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies, hospitals, and healthcare providers. All three names on our list, Cardinal, Cencora, and McKesson, hold well over 90% of the US pharmaceutical wholesale industry. CAH trades at an 18x forward PE and a 15x P/FCF - this thing is generating cash for investors. It has a 1.3% dividend yield and is growing earnings 8% this year, and is expected to grow its earnings 12% next year. Gilead Sciences Josh — Gilead (GILD) , as you can see in the chart above, is not done going up. This name has been on the list for most of the year so far. At the market lows this spring, it never violated its upward-sloping 200-day moving average — didn't even pay it a visit. And just for fun, below is the "forever" chart back to the company's IPO. I am a believer that price has memory, but I'm not sure there are still a lot of shareholders hanging around here from the last time it traded near the $120 level a decade ago. That said, I wouldn't be surprised to see a battle at that old high as new shareholders buy from sellers who are just thrilled to be getting out break-even. That's what makes a market. Sean — Gilead Sciences (GILD) has been on a run. Its experimental HIV prevention shot, lenacapavir, showed near-complete effectiveness in trials and is expected to generate $2–4 billion in peak annual sales—potentially transforming the HIV prevention market. The company has also posted solid financial results, with 2024 revenue and earnings rising due to strong performance in its HIV, liver disease, and oncology franchises. Analysts have raised price targets across the board, reflecting increased confidence in the company's pipeline and execution. GILD has a meaningful run rate of free cash flow (~$9.6B) and a growing pipeline of drugs for the future. DISCLOSURES: (None) All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. INVESTING INVOLVES RISK. EXAMPLES OF ANALYSIS CONTAINED IN THIS ARTICLE ARE ONLY EXAMPLES. THE VIEWS AND OPINIONS EXPRESSED ARE THOSE OF THE CONTRIBUTORS AND DO NOT NECESSARILY REFLECT THE OFFICIAL POLICY OR POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC. JOSH BROWN IS THE CEO OF RITHOLTZ WEALTH MANAGEMENT AND MAY MAINTAIN A SECURITY POSITION IN THE SECURITIES DISCUSSED. ASSUMPTIONS MADE WITHIN THE ANALYSIS ARE NOT REFLECTIVE OF THE POSITION OF RITHOLTZ WEALTH MANAGEMENT, LLC" TO THE END OF OR OUR DISCLOSURE. Click here for the full disclaimer.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

20 minutes ago

• Yahoo

Air Methods Partners with Mauna Loa Helicopters to Introduce Pilots to Air Medical Careers

Grass is Greener initiative provides real-world training, opens doors for next generation of pilots Mauna Loa Helicopters to Introduce Pilots to Air Medical Careers Mauna Loa Pilots Participate in Air Methods' Pilot Training in Denver GREENWOOD VILLAGE, CO, June 20, 2025 (GLOBE NEWSWIRE) -- Air Methods, the nation's leading air medical service provider, has partnered with Mauna Loa Helicopters to offer aspiring pilots a closer look at career opportunities in the helicopter emergency medical services (HEMS) industry. This partnership is part of Air Methods' new Grass is Greener initiative, which introduces newer pilots—and those currently flying in the tourism sector—to the unique mission and career potential of the air medical industry. The partnership launched last month with two Mauna Loa pilots participating in Air Methods' multi-day pilot training in Denver. The training featured classroom instruction, simulator sessions, and hands-on aircraft experience. Pilots also received education in key areas such as aeronautical decision-making, IFR and GPS navigation, and aircraft and equipment security. 'Our goal is to help bridge the gap between early-stage flight training and the highly specialized world of air medical services,' said Rob Hamilton, CEO of Air Methods. 'By partnering with respected flight schools like Mauna Loa Helicopters, we're opening doors for talented pilots to explore careers that combine aviation excellence with lifesaving impact.' Mauna Loa Helicopters, which currently has 32 flight instructors across its various campuses, plans to send a group of instructors to Air Methods' training program on a quarterly basis. This experience will provide pilots with real-world exposure to a national air medical provider, insights into industry standards and expectations, and valuable networking opportunities with experienced air medical professionals. For many instructors, it also represents a significant step forward in building a long-term career in professional aviation. 'Air Methods offers the kind of professional environment and mission-driven work that aligns with what many of our instructors aspire to,' said Benjamin Fouts, owner of Mauna Loa Helicopters, adding how he sees this partnership as a strategic move to better prepare his instructors for careers beyond flight training. 'We're excited to offer them access to this level of training, mentorship, and potential career pathways.' As the Grass is Greener initiative continues to grow, Air Methods remains committed to cultivating the next generation of air medical pilots by building strong relationships with flight schools across the country. ### About Mauna Loa Helicopters Mauna Loa Helicopters is a leading provider of helicopter and fixed-wing flight training, air tours, and utility services across the Hawaiian Islands. With bases throughout the islands and headquarters at Kona International Airport, the company delivers high-quality, FAA-approved training programs under Parts 141 and 61. We are proud to be an ACCSC-accredited institution and one of only two federally funded flight schools in the nation. Mauna Loa is also the only flight school in Hawaii approved by the Department of Education (DOE), setting us apart as a premier training provider in the region. In addition to training, Mauna Loa offers unforgettable aerial experiences for visitors and provides critical utility services, including external load operations, aerial survey, and agricultural support. The company operates a fleet of Robinson helicopters and fixed-wing aircraft. With a strong focus on safety, community engagement, and career development, Mauna Loa Helicopters continues to shape the future of aviation in Hawaii and beyond. About Air Methods Air Methods is the leading air medical service, delivering lifesaving care to more than 100,000 people every year. With 45 years of experience, Air Methods is the preferred partner for hospitals and one of the largest community-based providers of air medical services. Air Methods Ascend is the company's clinical education program, allowing critical care nurses and paramedics best-in-class training opportunities using high-fidelity mannequins, virtual reality, and cadaver labs. Attachments Mauna Loa Helicopters to Introduce Pilots to Air Medical Careers Mauna Loa Pilots Participate in Air Methods' Pilot Training in Denver CONTACT: Denisse Coffman Air Methods 720-666-8499 media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

CNBC

40 minutes ago

• CNBC

Healthy Returns: What to know about the FDA's plan to speed up some drug reviews

The Food and Drug Administration proposed a dramatic expansion of its power to speed up drug reviews. The agency on Tuesday announced a new national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are supporting "U.S. national interests." Currently, the FDA has a deadline of 10 months after a company files a drug application to make an approval decision. That review period is shortened to six months if a company has been granted a priority review. "The ultimate goal is to bring more cures and meaningful treatments to the American public," FDA Commissioner Marty Makary said in a release. The new voucher program is different from the FDA's existing efforts to speed up review processes. The plan is designed for companies to submit "the lion's share" of a drug application to the agency even before they have final results from a pivotal clinical trial, a process that Makary said would reduce inefficiencies. The FDA may also grant an accelerated approval to products in the new voucher program, which will include "enhanced" communication with companies while their application is under review. The agency said it may extend the review period if the application is particularly complex or if there is insufficient information to support it. In the first year of the program, the FDA plans to give a limited number of vouchers to companies aligned with what it called "national health priorities." That includes addressing a health crisis in the U.S., delivering "more innovative cures" to Americans, addressing unmet public health needs and "increasing domestic drug manufacturing as a national security issue." The criteria come as the Trump administration encourages the pharmaceutical industry to reshore drug manufacturing through executive orders and potential tariffs on medicines imported into the U.S. In a note on Tuesday, Jefferies analyst Michael Yee said the criteria are broad but appear to be positive for the pharmaceutical industry. The program could be more effective than tariffs at encouraging drugmakers to bring their manufacturing to the U.S. But questions remain about the risks of speeding up drug reviews to as little as 30 days – the fastest the FDA has ever done. Another potential concern is whether the vouchers will be offered to political allies of the Trump administration, which could include companies that the FDA staff would normally scrutinize. We'll be looking out for more information on the new plan, so stay tuned. Feel free to send any tips, suggestions, story ideas and data to Annika at Virtual mental health startup Headspace announced a new direct-to-consumer therapy service this week called Therapy by Headspace. It's new territory for the company, which has spent the last decade selling its product to employers and health plans. The new service is available to more than 90 million Americans through Headspace's 45 in-network partnerships with insurers, including UnitedHealthcare, Cigna and Blue Cross Blue Shield. "Headspace now can be your mental health companion, be there for the everyday, whether you need help with sleep, stress, anxiety or you need access to a therapist," Headspace CEO Tom Pickett told CNBC in New York City on Wednesday. "We've got it all, and we've got it in an insurance-backed way, so that we can hopefully make this really inexpensive for you." Pickett, who took on the chief executive role in August, said the new Therapy by Headspace service is part of his vision to round out the company's consumer offerings. Therapy by Headspace users can access one-on-one video sessions with licensed therapists, and most covered members will pay between $0 and $35 per session. If a user's insurance does not cover the offering, they have the option to pay $149 per session out of pocket. Headspace said it plans to add more in-network partners over time. Users will also get three months of access to the sleep, meditation and stress exercises on the Headspace app, as well as Ebb, an artificial intelligence chatbot that can converse and direct people to the best available content. Over time, Ebb will also help generate personalized care plans for each member, Headspace said. "We have not been fully serving the audience that we have, and so launching therapy to consumers made a lot of sense," Pickett said. Headspace, founded in 2010, has raised a total of more than $350 million from investors like Khosla Ventures, Kaiser Permanente Ventures and Cigna Ventures, according to PitchBook. Pickett said Headspace is "running neutral" and in "a very healthy economic position right now." In the near term, the company isn't looking to raise more capital, and is instead focused on building out its offerings and inking new partnerships. "The ultimate goal is really to become the 'Easy Button' in mental health," Pickett said. Feel free to send any tips, suggestions, story ideas and data to Ashley at

Yahoo

an hour ago

• Yahoo

BMO says lenacapavir approval for prevention a ‘major win' for Gilead

Although largely as expected by investors, BMO Capital says lenacapavir's approval for prevention, now known as Yeztugo, marks 'a major win for Gilead (GILD)' in driving meaningful growth in its pre-exposure prophylaxis business. A clean label, strong clinical data, and a convenient twice yearly dosing regimen, in line with patient physician visits, should drive strong commercial adoption for Yeztugo, says the analyst, who has an Outperform rating and $120 price target on Gilead shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Disclaimer & DisclosureReport an Issue Cautious Optimism for Gilead Sciences Amid Yeztugo's Market Challenges Morgan Stanley says FDA approval of Yeztugo 'an expected positive' for Gilead Mizuho says Gilead Yeztugo label looks clean Gilead Sciences' Yeztugo Approval and Market Expansion Drive Buy Rating Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option